. Endocan as a novel endothelium-derived soluble dermatan sulfate proteoglycan has a molecular mass of around 20 kDa [3] . The contemporary CRRT membranes are able to remove molecules as large as 35 kDa. Hence, endocan could be removed by CRRT [4] . When new highly adsorptive membranes (HAM) with high absorptive abilities are used, the ability of CRRT to eliminate endocan could be even enhanced [4] . Therefore, the reliability of endocan during CRRT could be altered. De Freitas Caires et al. show that endocan appeared as a consistent good diagnostic criterion as well as procalcitonin (PCT) and could potentially be used for de-escalation therapy in the future (requiring new studies obviously) as PCT. Accordingly (if endocan is used for de-escalation in the future), falsely low endocan in CRRT patients, in turn, could lead to an earlier de-escalation of antibiotics and level of care for septic patients. There has been no investigation on the performance of endocan on patients who receive CRRT. Therefore, we believe there is a critical need for a future study with a focus on the performance of the currently known sepsis biomarkers among those who receive CRRT [5] .
Abbreviations AKI: Acute kidney injury; CRRT: Continuous renal replacement therapy; HAM: Highly adsorptive membranes; PCT: Procalcitonin; RRT: Renal replacement therapy; SA-AKI: Sepsis-associated AKI
